Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience.

LSD is being studied as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials showing significant symptom reductions and lasting effects. It works by modulating serotonin 5-HT2A receptors, which affects brain networks involved in emotion and cognition. In psychedelic-assisted psychotherapy, mystical-type experiences during LSD use are linked to improved well-being. This review covers LSD's pharmacokinetics, mechanisms, and safety concerns, including cardiovascular risks, emotional vulnerability, and the risk of hallucinogen-persisting perception disorder (HPPD). Challenges include small sample sizes, variable dosing, and regulatory restrictions. Future research should focus on standardization, pharmacogenetics, and personalized treatment.

Study at a glance

Abstract

Lysergic acid diethylamide (LSD) is gaining renewed interest as a potential treatment for anxiety, depression, and alcohol use disorder, with clinical trials reporting significant symptom reductions and long-lasting effects. LSD modulates serotonin (5-HT2A) receptors, which, in turn, influence dysfunctional brain networks involved in emotional processing and cognition. It has also shown promise in psychedelic-assisted psychotherapy, where mystical-type experiences are linked to improved psychological well-being. This review examines LSD's pharmacokinetics, neurobiological mechanisms, and safety considerations, including cardiovascular risks, emotional vulnerability, and the potential for hallucinogen-persisting perception disorder (HPPD). Challenges such as small sample sizes, variable dosing protocols, and regulatory restrictions limit large-scale trials. Future research should focus on standardization, pharmacogenetic influences, and personalized treatment strategies to ensure its safe and effective integration into clinical practice.